These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 21320309)

  • 21. Oncolytic targeting of androgen-sensitive prostate tumor by the respiratory syncytial virus (RSV): consequences of deficient interferon-dependent antiviral defense.
    Echchgadda I; Chang TH; Sabbah A; Bakri I; Ikeno Y; Hubbard GB; Chatterjee B; Bose S
    BMC Cancer; 2011 Jan; 11():43. PubMed ID: 21276246
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Oncolytic vaccinia virus disrupts tumor-associated vasculature in humans.
    Breitbach CJ; Arulanandam R; De Silva N; Thorne SH; Patt R; Daneshmand M; Moon A; Ilkow C; Burke J; Hwang TH; Heo J; Cho M; Chen H; Angarita FA; Addison C; McCart JA; Bell JC; Kirn DH
    Cancer Res; 2013 Feb; 73(4):1265-75. PubMed ID: 23393196
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Vaccinia virus injected human tumors: oncolytic virus efficiency predicted by antigen profiling analysis fitted boolean models.
    Cecil A; Gentschev I; Adelfinger M; Dandekar T; Szalay AA
    Bioengineered; 2019 Dec; 10(1):190-196. PubMed ID: 31142183
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Preferential colonization of metastases by oncolytic vaccinia virus strain GLV-1h68 in a human PC-3 prostate cancer model in nude mice.
    Donat U; Weibel S; Hess M; Stritzker J; Härtl B; Sturm JB; Chen NG; Gentschev I; Szalay AA
    PLoS One; 2012; 7(9):e45942. PubMed ID: 23049897
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Delivery of oncolytic vaccinia virus by matched allogeneic stem cells overcomes critical innate and adaptive immune barriers.
    Draganov DD; Santidrian AF; Minev I; Nguyen D; Kilinc MO; Petrov I; Vyalkova A; Lander E; Berman M; Minev B; Szalay AA
    J Transl Med; 2019 Mar; 17(1):100. PubMed ID: 30917829
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Vaccinia virus-mediated expression of human erythropoietin in tumors enhances virotherapy and alleviates cancer-related anemia in mice.
    Nguyen DH; Chen NG; Zhang Q; Le HT; Aguilar RJ; Yu YA; Cappello J; Szalay AA
    Mol Ther; 2013 Nov; 21(11):2054-62. PubMed ID: 23765443
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Characterization and evaluation of a new oncolytic vaccinia virus strain LIVP6.1.1 for canine cancer therapy.
    Gentschev I; Patil SS; Adelfinger M; Weibel S; Geissinger U; Frentzen A; Chen NG; Yu YA; Zhang Q; Ogilvie G; Szalay AA
    Bioengineered; 2013; 4(2):84-9. PubMed ID: 23093804
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Deciphering the Immunomodulatory Capacity of Oncolytic Vaccinia Virus to Enhance the Immune Response to Breast Cancer.
    Umer BA; Noyce RS; Franczak BC; Shenouda MM; Kelly RG; Favis NA; Desaulniers M; Baldwin TA; Hitt MM; Evans DH
    Cancer Immunol Res; 2020 May; 8(5):618-631. PubMed ID: 32127390
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Oncolytic vaccinia virus demonstrates antiangiogenic effects mediated by targeting of VEGF.
    Hou W; Chen H; Rojas J; Sampath P; Thorne SH
    Int J Cancer; 2014 Sep; 135(5):1238-46. PubMed ID: 24474587
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effective treatment of human breast tumor in a mouse xenograft model with herpes simplex virus type 1 specifying the NV1020 genomic deletion and the gBsyn3 syncytial mutation enabling high viral replication and spread in breast cancer cells.
    Israyelyan AH; Melancon JM; Lomax LG; Sehgal I; Leuschner C; Kearney MT; Chouljenko VN; Baghian A; Kousoulas KG
    Hum Gene Ther; 2007 May; 18(5):457-73. PubMed ID: 17536976
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Enhancing Expression of Functional Human Sodium Iodide Symporter and Somatostatin Receptor in Recombinant Oncolytic Vaccinia Virus for In Vivo Imaging of Tumors.
    Wang J; Arulanandam R; Wassenaar R; Falls T; Petryk J; Paget J; Garson K; Cemeus C; Vanderhyden BC; Wells RG; Bell JC; Le Boeuf F
    J Nucl Med; 2017 Feb; 58(2):221-227. PubMed ID: 27635026
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Synergistic antitumor effects of immune cell-viral biotherapy.
    Thorne SH; Negrin RS; Contag CH
    Science; 2006 Mar; 311(5768):1780-4. PubMed ID: 16556847
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A new MVA ancestor-derived oncolytic vaccinia virus induces immunogenic tumor cell death and robust antitumor immune responses.
    Rojas JJ; Van Hoecke L; Conesa M; Bueno-Merino C; Del Canizo A; Riederer S; Barcia M; Brosinski K; Lehmann MH; Volz A; Saelens X; Sutter G
    Mol Ther; 2024 Jul; 32(7):2406-2422. PubMed ID: 38734899
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Oncolytic efficacy of thymidine kinase-deleted vaccinia virus strain Guang9.
    Deng L; Fan J; Ding Y; Zhang J; Zhou B; Zhang Y; Huang B
    Oncotarget; 2017 Jun; 8(25):40533-40543. PubMed ID: 28465492
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antigen profiling analysis of vaccinia virus injected canine tumors: oncolytic virus efficiency predicted by boolean models.
    Cecil A; Gentschev I; Adelfinger M; Nolte I; Dandekar T; Szalay AA
    Bioengineered; 2014; 5(5):319-25. PubMed ID: 25482233
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Deletion of
    Potts KG; Irwin CR; Favis NA; Pink DB; Vincent KM; Lewis JD; Moore RB; Hitt MM; Evans DH
    EMBO Mol Med; 2017 May; 9(5):638-654. PubMed ID: 28289079
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Enhanced antitumor efficacy of a novel oncolytic vaccinia virus encoding a fully monoclonal antibody against T-cell immunoglobulin and ITIM domain (TIGIT).
    Zuo S; Wei M; He B; Chen A; Wang S; Kong L; Zhang Y; Meng G; Xu T; Wu J; Yang F; Zhang H; Wang S; Guo C; Wu J; Dong J; Wei J
    EBioMedicine; 2021 Feb; 64():103240. PubMed ID: 33581644
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of a new recombinant oncolytic vaccinia virus strain GLV-5b451 for feline mammary carcinoma therapy.
    Adelfinger M; Gentschev I; Grimm de Guibert J; Weibel S; Langbein-Laugwitz J; Härtl B; Murua Escobar H; Nolte I; Chen NG; Aguilar RJ; Yu YA; Zhang Q; Frentzen A; Szalay AA
    PLoS One; 2014; 9(8):e104337. PubMed ID: 25093734
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The addition of recombinant vaccinia HER2/neu to oncolytic vaccinia-GMCSF given into the tumor microenvironment overcomes MDSC-mediated immune escape and systemic anergy.
    de Vries CR; Monken CE; Lattime EC
    Cancer Gene Ther; 2015 Apr; 22(3):154-62. PubMed ID: 25633483
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A new recombinant vaccinia with targeted deletion of three viral genes: its safety and efficacy as an oncolytic virus.
    Yang S; Guo ZS; O'Malley ME; Yin X; Zeh HJ; Bartlett DL
    Gene Ther; 2007 Apr; 14(8):638-47. PubMed ID: 17268533
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.